Edwards Comments on German Court Decision
IRVINE, Calif., Oct. 23, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, announced that today the district court in Düsseldorf, Germany, granted Boston Scientific's request for a preliminary injunction on future commercial sales and, therefore, patient treatments using the Edwards SAPIEN 3 Ultra valve in Germany. The injunction will only become effective if Boston Scientific enforces it and provides a bond of €10 million.
The SAPIEN 3 Ultra valve is not yet approved for commercial sale and is the subject of a clinical study for European approval, which will continue. The decision has no effect on sales of the company's SAPIEN 3 or CENTERA valves. Edwards will promptly appeal and believes it will ultimately prevail.
This case pertains to the German part of Boston Scientific's European patent No. EP 2 949 292. The German court will hold a full hearing on the merits of the dispute in mid-2019.
About Edwards Lifesciences
Edwards Lifesciences, based in Irvine, Calif., is the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. Driven by a passion to help patients, the company collaborates with the world's leading clinicians and researchers to address unmet healthcare needs, working to improve patient outcomes and enhance lives. For more information, visit www.Edwards.com and follow us on Twitter @EdwardsLifesci.
CONTACT: Media, Sarah Huoh, +1-949-250-5070, or Investors, David K. Erickson, +1-949-250-6826, both of Edwards Lifesciences Corporation
